k 4

Vitamin K4 (Menadiol Diacetate) is a vitamin medicine for the treatment of blood coagulation disorders that caused by the lack of VK4.

K4 peptide exhibits potent antimicrobial properties, effectively targeting both Gram-positive and Gram-negative bacteria, particularly pathogenic strains like Staphylococcus aureus and Marine Vibrio species [1].

Vitamin K4 (Standard) is a reference standard for research and analysis in studies involving Vitamin K4. Vitamin K4 (Menadiol Diacetate) is a vitamin medicine for the treatment of blood coagulation disorders that caused by the lack of VK4.

Menaquinone-4 (Vitamin K2) is a vitamin K compound used as a hemostatic agent, and also as adjunctive therapy for the pain of osteoporosis.

MAP4K4-IN-3 (Compound 17), a serine/threonine protein kinase, may be a viable target for antidiabetic agents.

MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).

M4K2234 (Compound 26b) is a selective inhibitor of ALK2, displaying IC50 values of 5 nM for ALK2 and 2144 nM for ALK5. As a chemical probe for ALK1 and ALK2 kinases, it is used in mechanistic studies of BMP signaling and in cancer research where dysregulated ALK2 activity is implicated. Its high selectivity profile supports targeted investigations into ALK-mediated pathways.

TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor of TNIK and MAP4K4/HGK, with IC50 values of 1.29 nM and <10 nM, respectively, in human hepatic stellate cell LX-2, and is applicable in cancer and fibrosis inhibition [1].

H3K4(Me) (1-20) is a histone peptide; H3K4me is a complexly regulated post-translational modification closely associated with enhancers and promoters at active transcription genomic sites.

TAK1/MAP4K2 inhibitor 1 (compound 5) is a dual kinase inhibitor of TAK1 and MAP4K2 with IC50 values of 41.1 nM and 18.2 nM, respectively.

7A-methyl-5,6,7,7a-tetrahydro-1H,4H-imidazo[2,1-k]carbazol-2(3H)-one ,with CAS No. 258269-56-6, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 7A-methyl-5,6,7,7a-tetrahydro-1H,4H-imidazo[2,1-k]carbazol-2(3H)-one provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

K-Ras G12C-IN-4, is a potent Covalent Inhibitor of KRASG12C..

K-Ras ligand-Linker Conjugate 4 is a chemical compound combining a K-Ras recruiting ligand with a PROTAC linker, responsible for recruiting E3 ligases such as VHL, CRBN, MDM2, and IAP. It has the potential to be used in synthesizing PROTAC K-Ras Degrader-1, which shows a degradation efficacy of ≥70% in SW1573 cells[1].

K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.

PROTAC K-Ras Degrader-4 (Compound 4) is a proteolysis-targeting chimera (PROTAC) molecule designed to selectively degrade oncogenic mutants of K-Ras, effectively degrading KRASG12D in the GP5d cell line and KRASG12V in SW620 cells with DC50 of 1 nM and 13 nM, respectively; it concomitantly inhibits the downstream MAPK signaling pathway and represents a novel therapeutic strategy for cancer research targeting previously undruggable Ras mutations.

M4K2308, a selective ALK2 ether-linked inhibitor, demonstrates an IC50 of 2 nM and exhibits greater specificity for ALK2 over ALK5, with an IC50 of 224 nM for ALK5. This compound holds potential for research into Diffuse Intrinsic Pontine Glioma (DIPG).

M4K2281 is a potent and selective inhibitor of ALK2 with a half-maximal inhibitory concentration (IC50) of 2 nanomolar. In both biochemical and cellular assays, M4K2281 and M4K2308 demonstrate strong efficacy against ALK2. Moreover, M4K2281 exhibits a brain-to-plasma ratio that ranges from moderate to high.

M4K2009 is a selective and brain-penetrant ALK2 inhibitor (IC50 = 13 nM) effective against both wild-type (WT) and mutant ALK2 (G328V, R206H, and R258G), used for the treatment of diffuse intrinsic pontine glioma (DIPG).

PI3K/HDAC-IN-4 (Compound 31f) is a dual inhibitor targeting PI3K and HDAC, with an IC50 of 0.2μM. It demonstrates high selectivity for HDAC1-3, with IC50 values of 75.5 nM, 70.9 nM, and 1.9 nM, respectively. As a potent pan-PI3K inhibitor, PI3K/HDAC-IN-4 has IC50 values of 2.5 nM, 80.5 nM, 10.0 nM, and 57.2 nM for PI3Kα, β, δ, and γ, respectively. This compound effectively induces apoptosis in tumor cells by concurrently inhibiting the PI3K/AKT/mTOR signaling pathway and HDAC1-3. It shows significant antiproliferative activity across various tumor cell lines, such as MV4-11, Jeko-1, HL60, and MCF-7, with IC50 values of 0.2, 0.9, 0.8, and 1.5 μM, respectively. PI3K/HDAC-IN-4 is applicable in the study of lymphoma and leukemia.

K2-B4-5e is a PROTAC compound designed to target the degradation of BRD4 and androgen receptor (AR) through a KLHDC2-based E3 ligase mechanism. It effectively induces rapid and potent degradation of BET family proteins and AR within cells.

K2-B4-3e is an efficient BRD4 PROTAC, inducing BRD4 degradation with a DC50 value of 66 nM.

M4K2306 is a selective inhibitor of activin receptor-like kinase 2 (ALK2) with an IC50 of 7 nM. It is capable of penetrating the blood-brain barrier, exhibiting a brain-to-plasma ratio of 75.6.

PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent inhibitor targeting PI3K/Akt/mTOR pathways and tubulin polymerization. It induces apoptosis and causes cell cycle arrest at the G2/M phase. Additionally, PI3K/Akt/mTOR-IN-4 reduces the expression of p-PI3K, p-Akt, p-mTOR, and β-tubulin.

PI4Kβ/PKG-IN-1 (Compound 19) is an orally active dual inhibitor targeting phosphatidylinositol 4-kinase β (PI4Kβ) and cGMP-dependent protein kinase (PKG) in Plasmodium. This compound exhibits potent antimalarial activity and holds promise for malaria research.